{
    "organizations": [],
    "uuid": "6e1791a83d3030ca3035fd3acabd5e396b766279",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biotime-announces-dsmb-approval-to/brief-biotime-announces-dsmb-approval-to-proceed-to-cohort-4-of-the-opregen-clinical-trial-idUSASB0C96C",
    "ord_in_thread": 0,
    "title": "BRIEF-BioTime Announces DSMB Approval To Proceed To Cohort 4 Of The OpRegen Clinical Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 7 (Reuters) - Biotime Inc:\n* BIOTIME ANNOUNCES DSMB APPROVAL TO PROCEED TO COHORT 4 OF THE OPREGENÂ® CLINICAL TRIAL Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-07T21:25:00.000+02:00",
    "crawled": "2018-03-08T17:10:40.023+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "biotime",
        "inc",
        "biotime",
        "announces",
        "dsmb",
        "approval",
        "proceed",
        "cohort",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}